Biophysics Graduate Program, University of California Berkeley, Berkeley, CA 94720, USA.
J Mol Biol. 2012 Dec 7;424(3-4):109-24. doi: 10.1016/j.jmb.2012.07.014. Epub 2012 Jul 25.
Type II topoisomerases are required for the management of DNA superhelicity and chromosome segregation, and serve as frontline targets for a variety of small-molecule therapeutics. To better understand how these enzymes act in both contexts, we determined the 2.9-Å-resolution structure of the DNA cleavage core of human topoisomerase IIα (TOP2A) bound to a doubly nicked, 30-bp duplex oligonucleotide. In accord with prior biochemical and structural studies, TOP2A significantly bends its DNA substrate using a bipartite, nucleolytic center formed at an N-terminal dimerization interface of the cleavage core. However, the protein also adopts a global conformation in which the second of its two inter-protomer contact points, one at the C-terminus, has separated. This finding, together with comparative structural analyses, reveals that the principal site of DNA engagement undergoes highly quantized conformational transitions between distinct binding, cleavage, and drug-inhibited states that correlate with the control of subunit-subunit interactions. Additional consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIβ (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.
II 型拓扑异构酶对于管理 DNA 超螺旋和染色体分离至关重要,并且是各种小分子治疗药物的一线靶标。为了更好地了解这些酶在这两种情况下的作用,我们确定了与人拓扑异构酶 IIα(TOP2A)的 DNA 切割核心结合的双链 30 碱基对寡核苷酸的 2.9 Å 分辨率结构。与先前的生化和结构研究一致,TOP2A 使用形成于切割核心的 N 端二聚化界面的双切口、核酸酶中心显着弯曲其 DNA 底物。然而,该蛋白还采用了一种全局构象,其中其二聚体间接触点的第二个,即 C 末端的接触点已分离。这一发现,以及比较结构分析,表明 DNA 结合的主要部位在不同的结合、切割和药物抑制状态之间经历高度量化的构象转变,这与亚基-亚基相互作用的控制相关。进一步考虑我们的 TOP2A 模型,以及人拓扑异构酶 IIβ(TOP2B)的依托泊苷抑制复合物,提示可能存在修饰点,以开发针对拓扑异构酶 II 的特异性抑制剂,以克服拓扑异构酶 II 靶向化疗药物产生继发性恶性肿瘤的倾向。